Enclomiphene Dosage for Men: A Practical Guide

There is no single “correct” enclomiphene dosage for men, and there is no FDA-approved one either — because enclomiphene has not been approved by the FDA for any use. It is dispensed through compounding pharmacies and used off-label in men, which means every dose is provider-determined and individualized after a clinical evaluation. The numbers you will see below come from clinical trials. They exist to inform a conversation with a licensed provider — they are not a prescription, a recommendation, or a dose you should take on your own.

Why is there no official enclomiphene dose?

An “official” or “label” dose only exists for drugs the FDA has approved, where the agency has reviewed the dosing, manufacturing, and evidence. Enclomiphene never reached that point. Its developmental product, Androxal, received an FDA Complete Response Letter, announced on December 1, 2015; the agency found the Phase 3 study design inadequate to demonstrate clinical benefit and asked for additional trials. The product was never approved.

Today, enclomiphene is supplied as a compounded medication. Compounded drugs are not FDA-approved, and the FDA has not evaluated them for safety, quality, or efficacy. Enclomiphene citrate is currently a 503A Category 1 (“under evaluation”) bulk drug substance, meaning it may still be compounded under the FDA’s interim compounding policy. Category 1 status does not mean the drug is approved. For more on what the molecule is, see our explainer on what enclomiphene is.

What doses were studied in clinical trials?

Across the Repros Therapeutics development program, every pivotal study used once-daily oral dosing. Several discrete doses were tested. Here is what each trial actually used, with its population — figures should never be blended across studies.

Study (population)	Doses studied	Design / size
Wiehle et al., BJU International 2013 (men with secondary hypogonadism; baseline total T <350 ng/dL, LH <12 IU/L)	6.25, 12.5, 25 mg once daily	Randomized phase II, 6 weeks daily dosing (24-h T/LH profiling on Day 1 and Day 42); 48 enrolled, 44 per-protocol
Wiehle et al., Journal of Men’s Health 2014 (men with low/borderline testosterone)	12.5, 25, 50 mg once daily	14-day dose-ranging vs. T-gel vs. placebo; 52 men
Wiehle et al., Fertility and Sterility 2014 (ZA-203; secondary hypogonadism)	12.5, 25 mg once daily	~3-month phase II RCT vs. T-gel vs. placebo
2025 systematic review/meta-analysis (men with hypogonadism)	12.5–50 mg/day (pooled range)	10 RCTs; 819 patients

In the 14-day study of 52 men, enclomiphene produced a significant, dose-dependent rise in total testosterone across all doses versus placebo. In the 6-week Wiehle 2013 study (with 24-hour profiling on Day 42), the rise in serum total testosterone was more pronounced at 25 mg than at 12.5 mg. None of these figures is a recommended dose; each describes what researchers administered in a specific trial population.

Which doses were the most studied?

The two most-studied doses in men with secondary (functional) hypogonadism are 12.5 mg and 25 mg once daily. These were the doses used in the 3-month phase II trial (ZA-203, NCT01270841), where enclomiphene raised morning total testosterone, estradiol, LH, and FSH, raising testosterone similarly to 1% topical testosterone gel while preserving sperm counts — LH and FSH rose with enclomiphene but not with the gel. A common pattern across the Repros program was starting at 12.5 mg daily with up-titration to 25 mg, but that is a description of how trials were conducted, not guidance for a reader to follow.

For how enclomiphene compares to other approaches, our pieces on enclomiphene vs. TRT and enclomiphene vs. clomiphene add useful context.

How does a provider determine the right dose?

Because there is no label dose, a clinician individualizes everything. In practice that means a structured evaluation before anything is prescribed and ongoing monitoring afterward — the same logic used in the trials, where men were enrolled only after confirming low testosterone on more than one occasion.

Provider-determined dosing typically involves baseline labs (such as morning total testosterone, LH, FSH, and estradiol, plus general bloodwork), starting conservatively, and adjusting based on repeat labs and how a patient responds. Long-term safety is not established: the 2025 systematic review of 10 RCTs (819 patients) found significant improvements in total testosterone, LH, and FSH versus placebo but was underpowered for safety endpoints. Individual results vary. You can read more about tolerability in our overview of enclomiphene side effects.

Why should men never self-dose enclomiphene?

Enclomiphene is a selective estrogen receptor modulator (SERM) — the trans-isomer of clomiphene — and a drug, not a dietary supplement. Self-dosing skips the diagnosis, the baseline labs, the dose individualization, and the monitoring that make this kind of therapy appropriate and safer. It also risks treating symptoms that have other causes. Dosing, titration, and monitoring all require a licensed provider; product sold as a “supplement” containing clomiphene or enclomiphene is being sold illegally. Pharmacokinetics matter here too: enclomiphene has an elimination half-life of about 10 hours (Journal of Men’s Health 2014), much shorter than the cis-isomer (zuclomiphene) found in racemic clomiphene — one reason once-daily dosing was used in trials.

Frequently asked questions

Is there a standard enclomiphene dose for men?

No. Enclomiphene is not FDA-approved, so there is no official or standard label dose. In clinical trials, researchers studied roughly 6.25, 12.5, 25, and 50 mg once daily, but those are trial-derived figures, not recommendations. Any dose must be determined and monitored by a licensed provider, and patients should never self-dose.

What doses did the enclomiphene trials use?

The most-studied doses in men with secondary hypogonadism were 12.5 mg and 25 mg once daily, used in the 3-month ZA-203 phase II trial (Wiehle et al., Fertility and Sterility 2014). A separate 14-day study in 52 men tested 12.5, 25, and 50 mg, and a 6-week study in 48 men tested 6.25, 12.5, and 25 mg. These numbers describe individual studies and should not be blended.

Is compounded enclomiphene FDA-approved?

No. Compounded enclomiphene is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy. Its developmental product (Androxal) received an FDA Complete Response Letter, announced on December 1, 2015, and was never approved. Enclomiphene citrate remains a 503A Category 1 (“under evaluation”) substance, so it can still be compounded under the FDA’s interim policy.

How long does enclomiphene stay in the body?

Enclomiphene citrate is rapidly absorbed and has an elimination half-life of about 10 hours in hypogonadal men (Wiehle et al., Journal of Men’s Health 2014), which is much shorter than the cis-isomer found in racemic clomiphene. This pharmacokinetic profile is one reason the clinical trials used once-daily dosing.

How does a provider decide what dose to prescribe?

A provider individualizes the dose after a clinical evaluation and baseline bloodwork, then monitors over time and adjusts. In the trials, men were enrolled only after low testosterone was confirmed on more than one occasion, and labs such as morning testosterone, LH, FSH, and estradiol were tracked. Individual results vary, and long-term safety is not established.

Can enclomiphene affect fertility differently than testosterone therapy?

In the phase II ZA-203 trial, enclomiphene raised testosterone similarly to topical testosterone gel while preserving sperm counts and increasing LH and FSH, whereas the gel did not raise LH and FSH. This is one reason it is discussed as an option for men concerned about fertility, but any decision is individualized with a provider. See our comparison of enclomiphene vs. TRT for more.